Michael Storek
Cluster Head Sanofi
Seminars
Wednesday 3rd December 2025
Panel Discussion: Uncovering the Latest Technology in Preclinical Modelling Through the Promise of Humanized Complement Models in Drug Development
10:00 am
- Evaluating the utility of humanized complement models for testing complement inhibitors
- Delving into their advantages for human targeted agents
- Addressing key challenges such as incomplete humanization, low human protein expression and functional assay development
- Understanding how humanized complement models can be used to inform complement inhibitor dose prediction
Wednesday 3rd December 2025
Panel Discussion: Uncovering the Latest Technology in Preclinical Modelling Through the Promise of Humanized Complement Models in Drug Development
9:30 am
- Evaluating the utility of humanized complement models for testing complement inhibitors
- Delving into their advantages for human targeted agents
- Addressing key challenges such as incomplete humanization, low human protein expression and functional assay development
- Understanding how humanized complement models can be used to inform complement inhibitor dose prediction
Wednesday 3rd December 2025
Panel Discussion: Discussing the Next-Generation of Novel Modalities to be Used for Enhanced Delivery & Broader Impact in CNS & Ophthalmic Indications
12:00 pm
- Addressing the critical challenge of achieving sufficient complement inhibitor exposure in the CNS, a major reason for past failures with peripherally acting drugs
- Exploring novel delivery modalities like gene therapy, shuttle technologies that are in early development, to unlock the therapeutic potential of complement inhibition neurodegenerative diseases
- Highlighting the significant appeal and ongoing development of gene therapies for chronic ophthalmic conditions driven by complement
